Citigroup reiterated their buy rating on shares of Bayer (FRA:BAYN) in a research note issued to investors on Friday.
A number of other research analysts have also recently commented on BAYN. Baader Bank set a €140.00 ($172.84) target price on Bayer and gave the company a buy rating in a research note on Friday, October 20th. JPMorgan Chase & Co. restated a buy rating on shares of Bayer in a research note on Friday, October 20th. Sanford C. Bernstein set a €129.00 ($159.26) target price on Bayer and gave the company a buy rating in a research note on Monday, October 23rd. UBS Group set a €125.00 ($154.32) target price on Bayer and gave the company a buy rating in a research note on Monday, October 23rd. Finally, Berenberg Bank set a €121.00 ($149.38) target price on Bayer and gave the company a neutral rating in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. Bayer has a consensus rating of Buy and a consensus target price of €121.71 ($150.26).
Bayer (FRA:BAYN) opened at €98.54 ($121.65) on Friday. The company has a market capitalization of $81,520.00 and a P/E ratio of 23.30. Bayer has a one year low of €93.30 ($115.19) and a one year high of €123.82 ($152.86).
WARNING: “Citigroup Reiterates “Buy” Rating for Bayer (BAYN)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/citigroup-reiterates-buy-rating-for-bayer-bayn.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.